Patient P-01400
Therapy response
Stable
Tolerance
Favorable
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
48%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S17
- Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 54 SC-12 recommended — Supportive Compound SC-12
- Day 55 Patient accepted — Started SC-12 in the companion
- Day 59 GI-04 recommended — GI Support Protocol GI-04
- Day 60 Patient accepted — Started GI-04 in the companion
- Day 61 GI symptom burden −14% vs expected — Supportive Compound SC-12
- Day 67 Tolerance state changed — Unstable → Improving
- Day 68 GI symptom burden −32% vs expected — GI Support Protocol GI-04
- Day 72 ME-01 recommended — Monitoring Escalation ME-01
- Day 73 Patient accepted — Started ME-01 in the companion
- Day 74 Tolerance state changed — Unstable → Improving
- Day 76 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 45.
Primary contributors, last 14 days
- Nutritional resilience+4
- Treatment adherence-4
- Toxicity-4
- GI instability-3
What helped?
- Supportive Compound SC-12Day 54Result: symptom burden −14%
- GI Support Protocol GI-04Day 59Result: symptom burden −32%
- Monitoring Escalation ME-01Day 72Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
49%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 46 and rising
- Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 45
- WearableHRV 25 ms, trending down
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 41/100
- Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.2 · butyrate capacity 41/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 24 ms
- Sleep
- 6.8 h
- Steps
- 6,833
- Resting HR
- 71 bpm
Daily log: GI score 46, nutritional resilience 50, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 25% | S19 | AD-05 | improved | 61 |
| P-01377 | 24% | S11 | AD-05 | no change | 42 |
| P-01371 | 32% | S06 | CR-01 | improved | 63 |
| P-01708 | 32% | S07 | CR-01 | improved | 59 |
| P-01696 | 31% | S20 | CR-01 | improved | 59 |
| P-01835 | 31% | S17 | CR-01 | improved | 56 |
| P-01388 | 30% | S17 | CR-01 | improved | 59 |
| P-01442 | 30% | S13 | CR-01 | improved | 61 |
| P-01877 | 28% | S01 | CR-01 | improved | 67 |
| P-01430 | 27% | S05 | CR-01 | improved | 54 |
| P-01342 | 24% | S11 | DT-01 | improved | 48 |
| P-01336 | 52% | S03 | GI-04 | improved | 51 |